BMS-986525, OPDIVO 10 mg/mL concentrate for solution for infusion. clinical trials

A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination with Nivolumab in Participants with Relapsed/Refractory Small Cell Lung Cancer

This study is testing a new drug, BMS-986525, for people with small cell lung cancer that has come back or not responded to previous treatments. It's looking to see how safe the drug is, what side effects it might cause, and how well it works, both alone and when given with another medicine called nivolumab.